Neuronal signaling and the regulation of bone remodeling

Cellular and Molecular Life Sciences

Volumn 62, Issue 19-20, 2005, Pages 2339-2349

  Elefteriou, F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adrenergic receptor; Bone; Neuropeptide; Osteoblast; Osteoclast

Indexed keywords

ADRENERGIC RECEPTOR; CARRIER PROTEIN; DOPAMINE RECEPTOR; GLUTAMINE; NEUROPEPTIDE; RECEPTOR; SEROTONIN RECEPTOR;

BONE REMODELING; CENTRAL NERVOUS SYSTEM; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE MUTANT; NERVE CELL; NONHUMAN; OSTEOBLAST; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIOGENIC AMINES; BONE REMODELING; GLUTAMINE; NEURONS; NEUROPEPTIDES; OSTEOCLASTS; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, NEUROPEPTIDE; SIGNAL TRANSDUCTION;

EID: 27144514986     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-005-5175-3     Document Type: Review

References (125)

1. Karsenty G. and Wagner E.F. (2002) Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2(4): 389-406
2. Martin T. J., Ng K. W. and Suda T. (1989) Bone cell physiology. Endocrinol. Metab. Clin. North Am. 18(4): 833-858
3. Wagner E. F. and Karsenty G. (2001) Genetic control of skeletal development. Curr. Opin. Genet. Dev. 11(5): 527-532
4. Suda T., Udagawa N. and Takahashi N. (1996) Cells of bone: osteoclast generation. In: Principles of Bone Biology, 87-102. Bilezikian J. P., Raisz L. G. and Rodan G. A. (eds), Academic Press, San Diego
5. Teitelbaum S. L. (2000) Bone resorption by osteoclasts. Science 289: 1504-1508
6. Manolagas S. C. (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21(2): 115-137
7. Kleerekoper M. and Avioli L. V. (1998) Osteoporosis pathogenesis and therapy. In: Metabolic Bone Disease, L.V. Avioli and Krane S. M. (eds), Academic Press, San Diego
8. Melton L. J. 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14(Suppl. 1): S1-8
9. Riggs B. L., Khosla S. and Melton L. J. 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13(5): 763-773
10. Statement N. C. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6): 785-795
11. Karsenty G. (1999) The genetic transformation of bone biology. Genes Dev. 13(23): 3037-3051
12. Mundy G. R., Boyce B., Yoneda T., Bonewald L. F. and Roodman G. D. (1996) Cytokines and bone remodeling. In: Osteoporosis, vol. 1, 302313, Marcus R., Feldman D. and Kelsey J. (eds), Academic Press, San Diego
13. Perkins R. and Skirving A. P. (1987) Callus formation and the rate of healing of femoral fractures in patients with head injuries. J. Bone Joint Surg. Br. 69(4): 521-524
14. Aro H. (1985) Effect of nerve injury on fracture healing. Callus formation studied in the rat. Acta Orthop. Scand. 56(3): 233-237
15. Dauty M., Perrouin Verbe B., Maugars Y., Dubois C. and Mathe J. F. (2000) Supralesional and sublesional bone mineral density in spinal cord-injured patients. Bone 27(2): 305-309
16. Freehafer A. A. and Mast W. A. (1965) Lower extremity fractures in patients with spinal-cord injury. J. Bone Joint Surg. Am. 47: 683-694
17. Pearson J., Dancis J., Axelrod F. and Grover N. (1975) The sural nerve in familial dysautonomia. J. Neuropathol. Exp. Neurol. 34(5): 413-424
18. Poole K. E., Reeve J. and Warburton E. A. (2002) Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke 33(5): 1432-1436
19. Ramnemark A., Nyberg L., Lorentzon R., Englund U. and Gustafson Y. (1999) Progressive hemiosteoporosis on the paretic side and increased bone mineral density in the nonparetic arm the first year after severe stroke. Osteoporos Int. 9(3): 269-275
20. Felten D. L., Ackerman K. D., Wiegand S. J. and Felten S. Y. (1987) Noradrenergic sympathetic innervation of the spleen: I. Nerve fibers associate with lymphocytes and macrophages in specific compartments of the splenic white pulp. J. Neurosci. Res. 18(1): 28-36, 118 121
21. Felten D. L., Felten S. Y., Bellinger D. L., Carlson S. L., Ackerman K. D., Madden K. S. et al. (1987) Noradrenergic sympathetic neural interactions with the immune system: structure and function. Immunol. Rev. 100: 225-260
22. Livnat S., Madden K. S., Felten D. L. and Felten S. Y. (1987) Regulation of the immune system by sympathetic neural mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiatry 11(23): 145-152
23. Bjurholm A. (1991) Neuroendocrine peptides in bone. Int. Orthop. 15(4): 325-329
24. Bjurholm A., Kreicbergs A., Brodin E. and Schultzberg M. (1988) Substance P- and CGRP-immunoreactive nerves in bone. Peptides 9(1): 165-171
25. Bjurholm A., Kreicbergs A., Terenius L., Goldstein M. and Schultzberg M. (1988) Neuropeptide Y-, tyrosine hydroxylase-and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J. Auton. Nerv. Syst. 25(2 3): 119-125
26. Goto T., Yamaza T., Kido M. A. and Tanaka T. (1998) Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone. Cell Tissue Res. 293(1): 87-93
27. Hill E. L. and Elde R. (1991) Distribution of CGRP-, VIP-, D beta H-, SP- and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264(3): 469-480
28. Hohmann E. L., Elde R. P., Rysavy J. A., Einzig S. and Gebhard R. L. (1986) Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 232(4752): 868-871
29. Kellenberger S., Muller K., Richener H. and Bilbe G. (1998) Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 22(5): 471-478
30. Sisask G., Bjurholm A., Ahmed M. and Kreicbergs A. (1996) The development of autonomie innervation in bone and joints of the rat. J. Auton. Nerv. Syst. 59(1 2): 27-33
31. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K. L. et al. (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111(3): 305-317
32. Togari A., Arai M., Mizutani S., Mizutani S., Koshihara Y. and Nagatsu T. (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 233(2 3): 125-128
33. Imai S. and Matsusue Y. (2002) Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P- and tyrosine hydroxylase-containing nerves and the bone. Microsc. Res. Tech. 58(2): 61-69
34. Imai S., Tokunaga Y., Maeda T., Kikkawa M. and Hukuda S. (1997) Calcitonin gene-related peptide, substance P, and tyrosine hydroxylase- immunoreactive innervation of rat bone marrows: an immunohistochemical and ultrastructural investigation on possible efferent and afferent mechanisms. J. Orthop. Res. 15(1): 133-140
35. Irie K., Hara-Irie F., Ozawa H. and Yajima T. (2002) Calcitonin gene-related peptide (CGRP)-containing nerve fibers in bone tissue and their involvement in bone remodeling. Microsc. Res. Tech. 58(2): 85-90
36. Mach D. B., Rogers S. D., Sabino M. C., Luger N. M., Schwei M. J., Pomonis J. D. et al. (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113(1): 155-166
37. Asmus S. E., Parsons S. and Landis S. C. (2000) Developmental changes in the transmitter properties of sympathetic neurons that innervate the periosteum. J. Neurosci. 20(4): 1495-1504
38. Asmus S. E., Tian H. and Landis S. C. (2001) Induction of cholinergic function in cultured sympathetic neurons by periosteal cells: cellular mechanisms. Dev. Biol. 235(1): 1-11
39. Amara S. G., Jonas V., Rosenfeld M. G., Ong E. S. and Evans R. M. (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298(5871): 240-244
40. Bjurholm A., Kreicbergs A., Schultzberg M. and Lerner U. H. (1992) Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01. ROS 17/2.8. MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 7(9): 1011-1019
41. Kawase T. and Burns D. M. (1998) Calcitonin gene-related peptide stimulates potassium efflux through adenosine triphosphate-sensitive potassium channels and produces membrane hyperpolarization in osteoblastic UMR106 cells. Endocrinology 139(8): 3492-3502
42. Michelangeli V. P., Fletcher A. E., Allan E. H., Nicholson G. C. and Martin T. J. (1989) Effects of calcitonin gene-related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells. J. Bone Miner. Res. 4(2): 269-272
43. Cornish J., Gallon K. E., Lin C. Q., Xiao C. L., Gamble G. D., Cooper G. J. et al. (1999) Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J. Bone Miner. Res. 14(8): 1302-1309
44. Vignery A. and McCarthy T. L. (1996) The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts. Bone 18(4): 331-335
45. Bernard G. W. and Shih C. (1990) The osteogenic stimulating effect of neuroactive calcitonin gene-related peptide. Peptides 11(4): 625-632
46. Calland J. W., Harris S. E. and Carnes D. L. J. (1997) Human pulp cells respond to calcitonin gene-related peptide in vitro. J. Endod. 23(8): 485-489
47. Shih C. and Bernard G. W. (1997) Calcitonin gene related peptide enhances bone colony development in vitro. Clin. Orthop. Relat. Res. 334: 335-344
48. Hukkanen M., Konttinen Y. T., Santavirta S., Paavolainen P., Gu X. H., Terenghi G. et al. (1993) Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling. Neuroscience 54(4): 969-979
49. Li J., Ahmad T., Spetea T., Ahmed M. and Kreicbergs A. (2001) Bone reinnervation after fracture: a study in the rat. J. Bone Miner. Res. 16(8): 1505-1510
50. Drissi H., Hott M., Marie P. J. and Lasmoles F. (1997) Expression of the CT/CGRP gene and its regulation by dibutyryl cyclic adenosine monophosphate in human osteoblastic cells. J. Bone Miner. Res. 12(11): 1805-1814
51. Ballica R., Valentijn K., Khachatryan A., Guerder S., Kapadia S., Gundberg C. et al. (1999) Targeted expression of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J. Bone Miner. Res. 14(7): 1067-1074
52. Valentijn K., Gutow A. P., Troiano N., Gundberg C., Gilligan J. P. and Vignery A. (1997) Effects of calcitonin gene-related peptide on bone turnover in ovariectomized rats. Bone 21(3): 269-274
53. Schinke T., Liese S., Priemel M., Haberland M., Schilling A. F., Catala-Lehnen P. et al. (2004) Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J. Bone Miner. Res. 19(12): 2049-2056
54. Hara-Irie F., Amizuka N. and Ozawa H. (1996) Immunohistochemical and ultrastructural localization of CGRP-positive nerve fibers at the epiphyseal trabecules facing the growth plate of rat femurs. Bone 18(1): 29-39
55. Akopian A., Demulder A., Ouriaghli F., Corazza F., Fondu P. and Bergmann P. (2000) Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders? Peptides 21(4): 559-564
56. D'Souza S. M., MacIntyre I., Girgis S. I. and Mundy G. R. (1986) Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro. Endocrinology 119(1): 58-61
57. Roos B. A., Fischer J. A., Pignat W., Alander C. B. and Raisz L. G. (1986) Evaluation of the in vivo and in vitro calcium-regulating actions of noncalcitonin peptides produced via calcitonin gene expression. Endocrinology 118(1): 46-51
58. Zaidi M., Fuller K., Bevis J., GainesDas R. E., Chambers T. J. and MacIntyre I. (1987) Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study. Calcif. Tissue Int. 40(3): 149-154
59. Lundberg A., Lie A., Bjurholm A., Lehenkari P. P., Horton M. A., Lerner U. H. et al. (2000) Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone 27(6): 803-810
60. Mukohyama H., Ransjo M., Taniguchi H., Ohyama T. and Lerner U. H. (2000) The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem. Biophys. Res. Commun. 271(1): 158-163
61. Ransjo M., Lie A., Mukohyama H., Lundberg P. and Lerner U. H. (2000) Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. Biochem. Biophys. Res. Commun. 274(2): 400-404
62. Hohmann E. L., Levine L. and Tashjian A. H. Jr (1983) Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 3′,5′-monophosphate-dependent mechanism. Endocrinology 112(4): 1233-1239
63. Rahman S., Dobson R., Bunning R. A., Russell R. G. and Brown B. L. (1992) The regulation of connective tissue metabolism by vasoactive intestinal polypeptide. Regul. Pept. 37(2): 111-121
64. Offley S. C., Guo T. Z., Wei T., Clark J. D., Vogel H., Lindsey D. P. et al. (2005) Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J. Bone Miner. Res. 20(2): 257-267
65. Maayan C., Bar-On E., Foldes A. J., Gesundheit B. and Pollak R. D. (2002) Bone mineral density and metabolism in familial dysautonomia. Osteoporos. Int. 13(5): 429-433
66. Ghilardi J. R., Rohrich H., Lindsay T. H., Sevcik M. A., Schwei M. J., Kubota K. et al. (2005) Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain. J. Neurosci. 25(12): 3126-3131
67. Bliziotes M., McLoughlin S., Gunness M., Fumagalli F., Jones S. R. and Caron M. G. (2000) Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 26(1): 15-19
68. Westbroek I., van der Plas A., de Rooij K. E., Klein-Nulend J. and Nijweide J. (2001) Expression of serotonin receptors in bone. J. Biol. Chem. 276(31): 28961-28968
69. Bliziotes M. M., Eshleman A. J., Zhang X. W. and Wiren K. M. (2001) Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29(5): 477-486
70. Weintrob N., Cohen D., Klipper-Aurbach Y., Zadik Z. and Dickerman Z. (2002) Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch. Pediatr. Adolesc. Med. 156(7): 696-701
71. Warden S. J., Rohling A. G., Sanders M. S., Bliziotes M. M. and Turner C. H. (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146(2): 685-693
72. Goodship A. E., Lanyon L. E. and McFie H. (1979) Functional adaptation of bone to increased stress. An experimental study. J. Bone Joint Surg. Am. 61(4): 539-546
73. Battaglino R., Fu J., Spate U., Ersoy U., Joe M., Sedaghat L. et al. (2004) Serotonin regulates osteoclast differentiation through its transporter. J. Bone Miner. Res. 19(9): 1420-1431
74. Bhangu S., Genever P. G., Spencer G. J., Grewal T. S. and Skerry T. M. (2001) Evidence for targeted vesicular glutamate exocytosis in osteoblasts. Bone 29(1): 16-23
75. Chenu C. (2002) Glutamatergic innervation in bone. Microsc. Res. Tech. 58(2): 70-76
76. Chenu C. (2002) Glutamatergic regulation of bone remodeling. J. Musculoskelet. Neuronal Interact. 2(3): 282-284
77. Chenu C., Serre C. M., Raynal C., Burt-Pichat B., and Delmas P. D. (1998) Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 22(4): 295-299
78. Gu Y. and Publicover S. J. (2000) Expression of functional metabotropic glutamate receptors in primary cultured rat osteoblasts. Cross-talk with N-methyl-D-aspartate receptors. J. Biol. Chem. 275(44): 34252-34259
79. Mason D. J., Suva L. J., Genever P. G., Patton A. J., Steuckle S., Hillam R. A. et al. (1997) Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? Bone 20(3): 199-205
80. Serre, C.M., D. Farlay,D. Delmas, and C. Chenu, 1999, Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 25(6): 623-629
81. Patton A. J., Genever P. G., Birch M. A., Suva L. J. and Skerry T. M. (1998) Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone 22(6): 645-649
82. Smart T. G. (1997) Regulation of excitatory and inhibitory neurotransmitter-gated ion channels by protein phosphorylation. Curr. Opin. Neurobiol. 7(3): 358-367
83. Laketic-Ljubojevic, I., Suva L. J., Maathuis F. J., Sanders D. and Skerry T. M. (1999) Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. Bone 25(6): 631-637
84. Genever G. and Skerry T. M. (2001) Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone. FASEB J. 15(9): 1586-1588
85. Hinoi E., Fujimori S. and Yoneda Y. (2003) Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts. FASEB J. 17(11): 1532-1534
86. Skerry T. M. and Genever P. G. (2001) Glutamate signalling in non-neuronal tissues. Trends Pharmacol. Sci. 22(4): 174-181
87. Taylor A. F. (2002) Osteoblastic glutamate receptor function regulates bone formation and resorption. J. Musculoskelet. Neuronal Interact. 2(3): 285-290
88. Mohn A. R., Gainetdinov R. R., Caron M. G. and Koller B. H. (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98(4): 427-436
89. Peet N. M., Grabowski P. S., Laketic-Ljubojevic I. and Skerry T. M. (1999) The glutamate receptor antagonist MK801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiation. FASEB J. 13(15): 2179-2185
90. Gray C., Marie H., Arora M., Tanaka K., Boyde A., Jones S. et al. (2001) Glutamate does not play a major role in controlling bone growth. J. Bone Miner. Res. 16(4): 742-749
91. Mason D. J. (2004) Glutamate signalling and its potential application to tissue engineering of bone. Eur. Cell Mater. 7: 12-25; discussion 25 16
92. Espinosa L., Itzstein C., Cheynel H., Delmas D. and Chenu C. (1999) Active NMDA glutamate receptors are expressed by mammalian osteoclasts. J. Physiol. 518 (Pt 1): 47-53
93. Merle B., Itzstein, C., Delmas D. and Chenu C. (2003) NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J. Cell Biochem. 90(2): 424-436
94. Itzstein C., Espinosa J., Delmas P. D. and Chenu C. (2000) Specific antagonists of NMDA receptors prevent osteoclast sealing zone formation required for bone resorption. Biochem. Biophys. Res. Commun. 268(1): 201-209
95. Moore R. E., Smith C. K. 2nd, Bailey C. S., Voelkel E. F. and Tashjian A. H. Jr (1993) Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 23(3): 301-315
96. Elefteriou F., Ahn J. D., Takeda S., Starbuck M., Yang X., Liu X. et al. (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520
97. Greenfield E. M., Horowitz M. C. and Lavish S. A. (1996) Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J. Biol. Chem. 271(18): 10984-10989
98. Ducy P., Amling M., Takeda S., Priemel M., Schilling A. F., Beil T. et al. (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207
99. Owen T. A., Bortell R., Yocum S. A., Smock S. L., Zhang M., Abate C. et al. (1990) Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. Proc. Natl. Acad. Sci. USA 87(24): 9990-9994
100. Chambers T. J. (2000) Regulation of the differentiation and function of osteoclasts. J. Pathol. 192(1): 4-13
101. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M. T. and Martin T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20: 345-357
102. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T. et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2): 165-176
103. Ma Y. L., Cain R. L., Halladay D. L., Yang X., Zeng Q., Miles R. R. et al. (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142(9): 4047-4054
104. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H. C., Schinke T. et al. (2004) ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117(3): 387-398
105. Kondo A., Mogi M., Koshihara Y. and Togari A. (2001) Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem. Pharmacol. 61(3): 319-326
106. Cho E. S., Yu J. H., Kim M. S. and Yim M. (2004) Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by ind ucing TRANCE expression in mouse calvarial cells. Arch. Pharm. Res. 27(12): 1258-1262
107. Takami M., Cho E. S., Lee S. Y., Kamijo R. and Yim M. (2005) Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett. 579(3): 832-838
108. Kinoshita T., Kobayashi S., Ebara S., Yoshimura Y., Horiuchi H., TsutsumimotoT. et al. (2000) Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27(6): 811-817
109. Rawadi G., Ferrer C., Spinella-Jaegle S., Roman-Roman S., Bouali Y. and Baron R. (2001) 1-(5-oxohexyl)-3,7-Dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). Endocrinology 142(11): 4673-4682
110. Levasseur R., Marcelli C., Sabatier J. P., Dargent-Molina P. and Breart G. (2005) Beta-blocker use. bone mineral density and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J. Am. Geriatr. Soc. 53(3): 550-552
111. Pasco J. A., Henry M. J., Sanders K. M., Kotowicz M. A., SeemanE. and Nicholson G. C. (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res. 19(1): 19-24
112. Reid I. R., Gamble G. D., Grey A. B., Black D. M., Ensrud K. E., BrownerW. S. et al. (2005) beta-Blocker use, BMD and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. 20(4): 613-618
113. Schlienger R. G., Kraenzlin M. E., Jick S. S. and Meier C. R. (2004) Use of beta-blockers and risk of fractures. JAMA 292(11): 1326-1332
114. Romanello M., Moro L., Pirulli D., Crovella S. and D'Andrea P. (2001) Effects of cAMP on intercellular coupling and osteoblast differentiation. Biochem. Biophys. Res. Commun. 282(5): 1138-1144
115. Lecanda F., Warlow M., Sheikh S., Furlan F., Steinberg T. H. and Civitelli R. (2000) Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J. Cell Biol. 151(4): 931-944
116. Cancello R., Tounian A., Poitou C., and Clement K. (2004) Adiposity signals, genetic and body weight regulation in humans. Diabetes Metab. 30(3): 215-227
117. Dacquin R., Davey R. A., Laplace C., Levasseur R., Morris H. A., Goldring S. R. et al. (2004) Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol. 164(4): 509-514
118. Takeda S., Elefteriou F. and Karsenty G. (2003) Common Endocrine Control of Body Weight, Reproduction, and Bone Mass. Annu. Rev. Nutr.
119. Millet I. and Vignery A. (1997) The neuropeptide calcitonin gene-related peptide inhibits TNF-alpha but poorly induces IL-6 production by fetal rat osteoblasts. Cytokine 9(12): 999-1007
120. Mori T., Ogata T., Okumura H., Shibata T., Nakamura Y. and Kataoka K. (1999) Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochem. Biophys. Res. Commun. 262(2): 418-422
121. Lundberg P., Lundgren I., Mukohyama H., Lehenkari P. P., Horton M. A. and Lerner U. H. (2001) Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology 142(1): 339-347
122. Chenu C. (2002) Glutamatergic regulation of bone resorption. J. Musculoskelet. Neuronal Interact. 2(5): 423-431
123. Baldock A., Sainsbury A., Couzens M., Enriquez R. F., Thomas G. P., Gardiner E. M. et al. (2002) Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109(7): 915-921
124. Caverzasio J., Palmer G., Suzuki A. and Bonjour J. P. (2000) Evidence for the involvement of two pathways in activation of extracellular signal-regulated kinase (Erk) and cell proliferation by Gi and Gq protein-coupled receptors in osteoblast-like cells. J. Bone Miner. Res. 15(9): 1697-1706
125. Suzuki A., Palmer G., Bonjour J. P. and Caverzasio J. (1998) Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells. Bone 23(3): 197-203